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Abstract
© 2016,  Springer  Science+Business  Media  New  York.Previously,  it  was  shown  that  both
adrenaline and noradrenaline potentiate neuromuscular transmission,  but which one of  the
receptors mediates the facilitating effect of catecholamines is still unclear. In this study, we
have investigated the presence of  different  adrenoceptors  at  isolated preparations of  frog
cutaneous pectoris muscle by using methods of immunohistochemistry. The immunopositive
reaction was observed while using polyclonal antibodies to α1- (α1B and α1D), α2- (α2A, α2B,
and α2C), and β-adrenoceptors (β1, β2 and β3). In all the cases, the immunohistochemical
staining of the mentioned proteins was localized in the area of the synaptic contact. Thus, at the
neuromuscular junction, a wide range of α1-, α2- and β-adrenoceptors was found. It expands our
understanding of the endogenous mechanisms of cholinergic neurotransmission regulation and
elucidates the aspects of  the mechanisms of  action of  adrenergic agonists,  which are still
intensively studied or already used for treatment of neuromuscular disorders with a primary
neuro-  or  myopathology,  and  neuromuscular  diseases  characterized  by  a  neuromuscular
junction pathology.
http://dx.doi.org/10.1007/s12668-016-0319-5
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